TrialInternational journal of clinical oncology2024

Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.

Hideki Goto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.